Compare Fox Corp Class B (FOX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs McKesson Corporation — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.3× Fox Corp Class B's market cap, and Fox Corp Class B pays the higher dividend (1.02%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and McKesson Corporation for 74 Days on average.
| FOX | MCK | |
|---|---|---|
Market Cap | $25.36B | $108.46B |
Volume | 886,620 | 712,607 |
Sector | Media | Health |
52-Week High | $67.76 | $995.69 |
52-Week Low | $44.39 | $725.17 |
Typical Hold Time | 75 Days | 74 Days |
Enterprise Value | $28.72B | $115.00B |
Dividend Yield | 1.02% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.97, up 1.77% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $16.30B in 2025, with net income reaching $2.26B and a profit margin of 13.88%. The stock is supported by positive analyst sentiment, with a consensus price target of $84.75, indicating significant upside potential from current levels.
The outlook for FOX is favorable, driven by robust profitability and valuation metrics below industry averages. Key risks include a projected decline in 2026 net income and ongoing regulatory scrutiny of acquisitions. The stock presents a compelling opportunity for value-oriented investors, though monitoring execution on future earnings is critical.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
